Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03072160
Title Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

thyroid gland medullary carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.